Polyglutamine- and Temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Fodale, Valentina ^a   Kegulian, Natalie C ^b   Verani, Margherita ^a   Cariulo, Cristina ^a   Azzollini, Lucia ^a   Petricca, Lara ^a   Daldin, Manuel ^a   Boggio, Roberto ^a   Padova, Alessandro ^a   Kuhn, Rainer ^a,d   Pacifici, Robert ^c   Macdonald, Douglas ^c   Schoenfeld, Ryan C ^c   Park, Hyunsun ^c   Isas, J Mario ^b   Langen, Ralf ^b   Weiss, Andreas ^a,d   Caricasole, Andrea ^a  

^a IRBM   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE; RECOMBINANT PROTEIN; AMINO ACID; EPITOPE; HTT PROTEIN, HUMAN; MUTANT PROTEIN; NERVE PROTEIN; PEPTIDE; THIOREDOXIN;

ALPHA HELIX; ARTICLE; CELL LYSATE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; IMMUNOASSAY; MUTANT; PROTEIN ANALYSIS; PROTEIN CONFORMATION; SENSITIVITY ANALYSIS; TEMPERATURE DEPENDENCE; TIME RESOLVED FORSTER ENERGY TRANSFER; WILD TYPE; CHEMISTRY; DISEASE COURSE; EXON; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETICS; HEK293 CELL LINE; MUTATION; PROTEIN TERTIARY STRUCTURE; TEMPERATURE;

AMINO ACIDS; CIRCULAR DICHROISM; DISEASE PROGRESSION; EPITOPES; EXONS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; IMMUNOASSAY; MUTANT PROTEINS; MUTATION; NERVE TISSUE PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TEMPERATURE; THIOREDOXINS;

EID: 84914678999     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112262     Document Type: Article

References (70)

1. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983.0092-8674(93)90585-E [pii].
2. Hazeki N, Nakamura K, Goto J, Kanazawa I (1999) Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract. Biochem Biophys Res Commun 256: 361-366.S0006-291X(99)90337-6 [pii]; 10.1006/bbrc.1999.0337 [doi].
3. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285: 8808-8823.M109.075028 [pii]; 10.1074/jbc.M109.075028 [doi].
4. Lunkes A, Lindenberg KS, Ben-Haiem L, Weber C, Devys D, et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259-269. S1097276502006020 [pii].
5. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, et al. (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet 17: 2738-2751.ddn175 [pii]; 10.1093/hmg/ddn175 [doi].
6. Hoffner G, Island ML, Djian P (2005) Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J Neurochem 95: 125-136.JNC3348 [pii]; 10.1111/j.1471-4159.2005.03348.x [doi].
7. Legleiter J, Mitchell E, Lotz GP, Sapp E, Ng C, et al. (2010) Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 285: 14777-14790.M109.093708 [pii]; 10.1074/jbc.M109.093708 [doi].
8. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, et al. (2009) Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284: 10855-10867.M804813200 [pii]; 10.1074/jbc.M804813200 [doi].
9. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19: 2522-2534.
10. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, et al. (1999) Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol 46: 842-849.
11. Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, et al. (2012) Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem 287: 16017-16028.M111.252577 [pii]; 10.1074/jbc.M111.252577 [doi].
12. Wanker EE (2000) Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol Chem 381: 937-942. 10.1515/BC.2000.114 [doi].
13. Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, et al. (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol 19:.264-275.S1074-5521(12)00016-6 [pii]; 10.1016/j.chembiol.2011.12.020 [doi].
14. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993.
15. Maat-Schieman ML, Dorsman JC, Smoor MA, Siesling S, van Duinen SG, et al. (1999) Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J Neuropathol Exp Neurol 58: 129-137.
16. Ansaloni A, Wang ZM, Jeong JS, Ruggeri FS, Dietler G, et al. (2014) One-Pot Semisynthesis of Exon 1 of the Huntingtin Protein: New Tools for Elucidating the Role of Posttranslational Modifications in the Pathogenesis of Huntington's Disease. Angew Chem Int Ed Engl 53: 1928-1933. 10.1002/anie.201307510 [doi].
17. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, et al. (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol 7: 453-460.nchembio.582 [pii]; 10.1038/nchembio.582 [doi].
18. Bugg CW, Isas JM, Fischer T, Patterson PH, Langen R (2012) Structural features and domain organization of huntingtin fibrils. J Biol Chem 287: 31739-31746.M112.353839 [pii]; 10.1074/jbc.M112.353839 [doi].
19. Darnell G, Orgel JP, Pahl R, Meredith SC (2007) Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. J Mol Biol 374: 688-704.S0022-2836(07)01197-7 [pii]; 10.1016/j.jmb.2007.09.023 [doi].
20. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, et al. (2009) Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64: 828-840.S0896-6273(09)00936-2 [pii]; 10.1016/j.neuron.2009.11.020 [doi].
21. Lakhani VV, Ding F, Dokholyan NV (2010) Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences. PLoS Comput Biol 6: e1000772. 10.1371/journal.pcbi.1000772 [doi].
22. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743. 10.1038/35099568 [doi]; 35099568 [pii].
23. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, et al. (2009) IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 187: 1083-1099.jcb.200909067 [pii]; 10.1083/jcb.200909067 [doi].
24. Kim MW, Chelliah Y, Kim SW, Otwinowski Z, Bezprozvanny I (2009) Secondary structure of Huntingtin amino-terminal region. Structure17: 1205-1212.S0969-2126(09)00299-8 [pii]; 10.1016/j.str.2009.08.002 [doi].
25. Kim M (2013) Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N-terminal region with insertion of three histidine residues. Prion 7: 221-228.23807 [pii]; 10.4161/pri.23807[doi].
26. Caron NS, Desmond CR, Xia J, Truant R (2013) Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc Natl Acad Sci U S A 110: 14610-14615.1301342110 [pii]; 10.1073/pnas.1301342110 [doi].
27. Ko J, Ou S, Patterson PH (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 56: 319-329.S0361-9230(01)00599-8 [pii].
28. Mathis G (1993) Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 39: 1953-1959.
29. Degorce F, Card A, Soh S, Trinquet E, Knapik GP, et al. (2009) HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications. Curr Chem Genomics 3: 22-32. 10.2174/1875397300903010022 [doi].
30. Khoshnan A, Ko J, Patterson PH (2002) Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A 99: 1002-1007. 10.1073/pnas.022631799 [doi]; 022631799 [pii].
31. Legleiter J, Lotz GP, Miller J, Ko J, Ng C, et al. (2009) Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J Biol Chem 284: 21647-21658.M109.016923 [pii]; 10.1074/jbc.M109.016923 [doi].
32. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, et al. (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem395: 8-15.S0003-2697(09)00541-7 [pii]; 10.1016/j.ab.2009.08.001 [doi].
33. Ma K, Wang K (2003) Malleable conformation of the elastic PEVK segment of titin: non-co-operative interconversion of polyproline II helix, beta-turn and unordered structures. Biochem J 374: 687-695. 10.1042/BJ20030702 [doi]; BJ20030702 [pii].
34. Langsetmo K, Fuchs J, Woodward C (1989) Escherichia coli thioredoxin folds into two compact forms of different stability to urea denaturation. Biochemistry 28: 3211-3220.
35. Rohl CA, Baldwin RL (1997) Comparison of NH exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. Biochemistry 36: 8435-8442. 10.1021/bi9706677 [doi]; bi9706677 [pii].
36. Luo P, Baldwin RL (1997) Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 36: 8413-8421. 10.1021/bi9707133 [doi]; bi9707133 [pii].
37. Lees JG, Miles AJ, Wien F, Wallace BA (2006) A reference database for circular dichroism spectroscopy covering fold and secondary structure space. Bioinformatics 22: 1955-1962.btl327 [pii]; 10.1093/bioinformatics/btl327 [doi].
38. Whitmore L, Wallace BA (2004) DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 32: W668-W673. 10.1093/nar/gkh371 [doi]; 32/suppl-2/W668 [pii].
39. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R (2007) Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 16: 2600-2615.ddm217 [pii]; 10.1093/hmg/ddm217 [doi].
40. Michalek M, Salnikov ES, Bechinger B (2013) Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach. Biophys J 105: 699-710.S0006-3495(13)00738-8 [pii]; 10.1016/j.bpj.2013.06.030 [doi].
41. Darnell GD, Derryberry J, Kurutz JW, Meredith SC (2009) Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect. Biophys J 97: 2295-2305.S0006-3495(09)01312-5 [pii]; 10.1016/j.bpj.2009.07.062 [doi].
42. Klein FA, Zeder-Lutz G, Cousido-Siah A, Mitschler A, Katz A, et al. (2013) Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10. Hum Mol Genet 22: 4215-4223.ddt273 [pii]; 10.1093/hmg/ddt273 [doi].
43. Liebman SW, Meredith SC (2010) Protein folding: sticky N17 speeds huntingtin pile-up. Nat Chem Bio6: 7-8.nchembio.279 [pii]; 10.1038/nchembio.279 [doi].
44. Ehrnhoefer DE, Sutton L, Hayden MR (2011) Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 17: 475-492.1073858410390378 [pii]; 10.1177/1073858410390378 [doi].
45. Aiken CT, Steffan JS, Guerrero CM, Khashwji H, Lukacsovich T, et al. (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J Biol Chem 284: 29427-29436.M109.013193 [pii]; 10.1074/jbc.M109.013193 [doi].
46. Maiuri T, Woloshansky T, Xia J, Truant R (2013) The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal. Hum Mol Genet 22: 1383-1394.dds554 [pii]; 10.1093/hmg/dds554 [doi].
47. Zheng Z, Li A, Holmes BB, Marasa JC, Diamond MI (2013) An N-terminal nuclear export signal regulates trafficking and aggregation of Huntingtin (Htt) protein exon 1. J Biol Chem 288: 6063-6071.M112.413575 [pii]; 10.1074/jbc.M112.413575 [doi].
48. Dlugosz M, Trylska J (2011) Secondary structures of native and pathogenic huntingtin N-terminal fragments. J Phys Chem B 115: 11597-11608. 10.1021/jp206373g [doi].
49. Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421: 466-490.S0022-2836(12)00084-8 [pii]; 10.1016/j.jmb.2012.01.030 [doi].
50. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103: 11045-11050.0604547103 [pii]; 10.1073/pnas.0604547103 [doi].
51. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, et al. (2008) Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 28: 9013-9020.28/36/9013 [pii]; 10.1523/JNEUROSCI.2747-08.2008 [doi].
52. Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 29: 13589-13602.29/43/13589 [pii]; 10.1523/JNEUROSCI.4286-09.2009 [doi].
53. Tam S, Spiess C, Auyeung W, Joachimiak L, Chen B, et al. (2009) The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 16: 1279-1285.nsmb.1700 [pii]; 10.1038/nsmb.1700 [doi].
54. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, et al. (2009) Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 16: 380-389.nsmb.1570 [pii]; 10.1038/nsmb.1570 [doi].
55. Crick SL, Ruff KM, Garai K, Frieden C, Pappu RV (2013) Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation. Proc Natl Acad Sci U S A 110: 20075-20080.1320626110 [pii]; 10.1073/pnas.1320626110 [doi].
56. Williamson TE, Vitalis A, Crick SL, Pappu RV (2010) Modulation of polyglutamine conformations and dimer formation by the N-terminus of huntingtin. J Mol Biol 396: 1295-1309.S0022-2836(09)01522-8 [pii]; 10.1016/j.jmb.2009.12.017 [doi].
57. Truant R, Atwal RS, Desmond C, Munsie L, Tran T (2008) Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J 275: 4252-4262.EJB6561 [pii]; 10.1111/j.1742-4658.2008.06561.x [doi].
58. Gusella J, Macdonald M (2002) No post-genetics era in human disease research. Nat Rev Genet 3: 72-79. 10.1038/nrg706 [doi]; nrg706 [pii].
59. Gusella JF, Macdonald ME (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109-115. 10.1038/nrd1077 [doi].
60. Todd TW, Lim J (2013) Aggregation formation in the polyglutamine diseases: protection at a cost? Mol Cells 36: 185-194. 10.1007/s10059-013-0167-x [doi].
61. Orr HT (2012) Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Curr Opin Genet Dev 22: 251-255.S0959-437X(12)00002-0 [pii]; 10.1016/j.gde.2012.01.001 [doi].
62. Blum ES, Schwendeman AR, Shaham S (2013) PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol 23: 168-174.S0962-8924(12)00216-4 [pii]; 10.1016/j.tcb.2012.11.003 [doi].
63. O'Rourke JG, Gareau JR, Ochaba J, Song W, Rasko T, et al. (2013) SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Rep 4: 362-375.S2211-1247(13)00326-4 [pii]; 10.1016/j.celrep.2013.06.034 [doi].
64. Cui X, Liang Q, Liang Y, Lu M, Ding Y, et al. (2014) TR-FRET Assays of Huntingtin Protein Fragments Reveal Temperature and PolyQ Length-Dependent Conformational Changes. Sci Rep 4.: 5601srep05601 [pii]; 10.1038/srep05601 [doi].
65. Bennett MJ, Huey-Tubman KE, Herr AB, West AP Jr, Ross SA, et al. (2002) A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A 99: 11634-11639. 10.1073/pnas.182393899 [doi]; 182393899 [pii].
66. Paganetti P, Weiss A, Trapp M, Hammerl I, Bleckmann D, et al. (2009) Development of a method for the high-throughput quantification of cellular proteins. Chembiochem 10: 1678-1688. 10.1002/cbic.200900131 [doi].
67. Brooks E, Arrasate M, Cheung K, Finkbeiner SM (2004) Using antibodies to analyze polyglutamine stretches. Methods Mol Biol 277: 103-128.1-59259-804-8 103 [pii]; 10.1385/1-59259-804-8:103 [doi].
68. Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, et al. (2005) Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 1065-1068.S1744309105036547 [pii]; 10.1107/S1744309105036547 [doi].
69. Jayasinghe SA, Langen R (2004) Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J Biol Chem 279: 48420-48425. 10.1074/jbc.M406853200 [doi]; M406853200 [pii].
70. Lennon BW, Williams CH Jr, Ludwig ML (2000) Twists in catalysis: alternating conformations of Escherichia coli thioredoxin reductase. Science 289: 1190-11948731 [pii].